Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 119Squamous Cell Carcinoma of Head and Neck 60Melanoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 46Lung Neoplasms 45Triple Negative Breast Neoplasms 44Neoplasm Metastasis 42Breast Neoplasms 40Neoplasms 36Colorectal Neoplasms 31Head and Neck Neoplasms 27Endometrial Neoplasms 26Carcinoma, Renal Cell 26Ovarian Neoplasms 23Carcinoma, Transitional Cell 22Urinary Bladder Neoplasms 20Stomach Neoplasms 15Carcinoma 14Pancreatic Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Esophageal Neoplasms 12Sarcoma 11Hodgkin Disease 11Brain Neoplasms 11Carcinoma, Squamous Cell 10Cholangiocarcinoma 9Carcinoma, Hepatocellular 9Skin Neoplasms 8Esophageal Squamous Cell Carcinoma 8

Interventions

Gemcitabine 8Cisplatin 8pembrolizumab 4durvalumab 4Specimen Handling 3Platinum 3Oxaliplatin 3Leucovorin 31,2-diaminocyclohexaneplatinum II citrate 3Taxes 2Nivolumab 2Magnetic Resonance Spectroscopy 2Folfox protocol 2Fluorouracil 2Biopsy 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zanidatamab 1trastuzumab deruxtecan 1tivozanib 1peposertib 1guadecitabine 1fludarabine 1dehydroftorafur 1binimetinib 1avelumab 1atezolizumab 1Trastuzumab 1Radiation Dose Hypofractionation 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × pembrolizumab × 90 days × Clear all
NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04924062 2026-04-15

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
158 enrolled 19 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06178445 2026-03-27

TRAP-BTC

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
24 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
1,069 enrolled 19 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡